Enveric Biosciences, Inc. announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of Theravance, to its Board of Directors. Mr. Webb has more than 25 years of experience in healthcare and life sciences. He specializes in early-stage companies focused on targeted therapeutics and molecular diagnostics.

Currently, he is the President and CEO of CXL Ophthalmics. He has held Executive Chairman, Chairman, and CEO roles for numerous biotechnology companies, including venture-backed and NASDAQ-listed entities, as well as was previously the Chairman of MassBio, a biotechnology industry trade organization serving one of the top life sciences clusters in the world. Ms. O'Neil currently serves as the Chief Strategy Officer of ECRI, a nonprofit organization with 500 employees focused on advancing evidence-based, effective healthcare globally.

Ms. O'Neil has over two decades of private equity, fundraising and operating experience, and has sat on several boards and audit committees of companies ranging from small entrepreneurial start-ups to global multi-billion dollar corporate enterprises. Mr. Pasqualone was most recently the Chief Business Officer of Theravance Biopharma, following a 26-year career with Bristol-Myers Squibb (BMS). At BMS, he held executive leadership positions in the U.S. and globally, including President of the Intercontinental Region: Latin America, Middle East and Africa, and prior to that, President of Southern Europe.

In the U.S., he ran the Oncology business as well as strategic oversight for the development and commercialization of the global oncology franchise. Mr. Pasqualone holds an M.B.A. from University of Dayton and a B.S. in Marketing from Bowling Green State University in Ohio.